Treatment
Table 3. Antimicrobials Frequently Used Drug
Dose
Antivirals Acyclovir (Zovirax®
)
Famciclovir (Famvir® Foscarnetb,c (Foscavir® Valacyclovir (Valtrex®
)
) )
)b
200-800 mg 2-5 x dailyb > 18 yrs: 250-1000 mg bid b
40 mg/kg slow IV infusion q8h or q12h 1 gram dailyb
Neuraminidase Inhibitors for Influenza Oseltamivir (Tamiflu®
≤ 15 kg: 30 mg bid 15 kg to 23 kg: 45 mg bid 23 kg to 40 kg: 60 mg bid > 40 kg: 75 mg bid
Zanamivir (Relenza® CSFs
Filgrastim (G-CSF) (Neupogen®
)
Pegfilgrastim (G-CSF) (Neulasta®
)
Pegfilgrastim (G-CSF) (Neulasta®
)
Sargramostim (GM-CSF) (Leukine®
)
NOTE: See PI for full prescribing information. a
dosing regimens for aminoglycosides should be based on adjusted body weight. b
c Approved for mucocutaneous acyclovir-resistant HSV infections.
Serum drug concentration monitoring should be considered for dosage individualization. Initial Adjust for renal impairment.
Table 4. Indications for Addition of Gram-positive Active Antibiotics to the Empirical Regimen for Fever and Neutropenia
Hemodynamic instability or other evidence of severe sepsis Pneumonia documented radiographically
Positive blood culture for Gram-positive bacteria, before final identification and susceptibility testing is available
Clinically suspected serious catheter-related infections (eg, chills or rigors with infusion through catheter, cellulitis around the catheter entry/exit site) Skin or soſt tissue infection at any site Colonization with MRSA, VRE or with penicillin-resistant Streptococcus pneumoniae
Severe mucositis, if fluoroquinolone prophylaxis has been given and ceſtazidime is employed as empirical therapy.
10 250 mcg/m2/day IV 6 mg subcutaneously 5 mcg/kg/day ) > 7 yrs: 2 inh (10 mg) q12h 5 mcg/kg/day
Treat for 5 days
(continued)
(Br
and)
